Patient, treatment, and disease characteristics of the European CAR-T recipients enrolled in this study
| Characteristics . | European CAR-T recipients (N = 389) . |
|---|---|
| Age, median (mean; range), y | 61 (59; 18-85) |
| >70 y, n (%) | 68 (17) |
| Female, n (%) | 142 (37) |
| Country, n (%) | |
| Austria | 9 (2) |
| Belgium | 27 (7) |
| France | 129 (33) |
| Germany | 57 (15) |
| Ireland | 6 (2) |
| Italy | 12 (3) |
| The Netherlands | 95 (24) |
| Portugal | 7 (2) |
| Spain | 15 (4) |
| United Kingdom | 32 (8) |
| Highest level of education completed, n (%) | |
| No schooling completed | 1 (<1) |
| Primary school (elementary) | 17 (4) |
| Secondary education (high school) | 154 (40) |
| Postsecondary education (college/university) | 140 (36) |
| Postgraduate (Master/PhD) | 60 (15) |
| Prefer not to say | 17 (4) |
| Diagnosis, n (%) | |
| Lymphoma | 333 (86) |
| Multiple myeloma | 30 (8) |
| Leukemia | 24 (6) |
| Unknown | 2 (1) |
| Time (months) since CAR-T infusion, n (%) | |
| ≤3 | 64 (16) |
| 4-12 | 106 (27) |
| 13-24 | 97 (25) |
| >24 | 122 (31) |
| Treatment setting, n (%) | |
| Clinical trial | 131 (34) |
| Standard of care | 232 (60) |
| Unknown | 26 (7) |
| Received bridging therapy,∗n (%) | 213 (55) |
| Unknown | 19 (5) |
| Hospital admission duration fromCAR-Tinfusion, median (mean; range) | 16 days (20; 0-210)† |
| Admitted to ICU, n (%) | 93 (24) |
| Travel distance toCAR-Ttreatment center, median (mean; IQR) | 50 km (78; 20-101) |
| Temporary stay needed to be close enough to hospital during first month after CAR-T infusion, n (%) | 82 (21) |
| Of whom received financial support from an official authority‡ to rent a temporary stay, n (%) | |
| Yes | 28 (34) |
| No | 39 (48) |
| Not applicable, for example stay with relatives or friends who live close to the hospital | 15 (18) |
| Experienced cytokine release syndrome, n (%) | 243 (62) |
| Unknown | 12 (3) |
| Experienced neurological side effects,n (%) | 163 (42) |
| Unknown | 13 (3) |
| Experienced infections, n (%) | 100 (26) |
| Unknown | 26 (7) |
| Experienced cytopenia(s), n (%) | 290 (75) |
| Unknown | 51 (13) |
| Disease progression after CAR-T therapy, n (%) | 76 (20) |
| Unknown/awaiting response | 29 (7) |
| Characteristics . | European CAR-T recipients (N = 389) . |
|---|---|
| Age, median (mean; range), y | 61 (59; 18-85) |
| >70 y, n (%) | 68 (17) |
| Female, n (%) | 142 (37) |
| Country, n (%) | |
| Austria | 9 (2) |
| Belgium | 27 (7) |
| France | 129 (33) |
| Germany | 57 (15) |
| Ireland | 6 (2) |
| Italy | 12 (3) |
| The Netherlands | 95 (24) |
| Portugal | 7 (2) |
| Spain | 15 (4) |
| United Kingdom | 32 (8) |
| Highest level of education completed, n (%) | |
| No schooling completed | 1 (<1) |
| Primary school (elementary) | 17 (4) |
| Secondary education (high school) | 154 (40) |
| Postsecondary education (college/university) | 140 (36) |
| Postgraduate (Master/PhD) | 60 (15) |
| Prefer not to say | 17 (4) |
| Diagnosis, n (%) | |
| Lymphoma | 333 (86) |
| Multiple myeloma | 30 (8) |
| Leukemia | 24 (6) |
| Unknown | 2 (1) |
| Time (months) since CAR-T infusion, n (%) | |
| ≤3 | 64 (16) |
| 4-12 | 106 (27) |
| 13-24 | 97 (25) |
| >24 | 122 (31) |
| Treatment setting, n (%) | |
| Clinical trial | 131 (34) |
| Standard of care | 232 (60) |
| Unknown | 26 (7) |
| Received bridging therapy,∗n (%) | 213 (55) |
| Unknown | 19 (5) |
| Hospital admission duration fromCAR-Tinfusion, median (mean; range) | 16 days (20; 0-210)† |
| Admitted to ICU, n (%) | 93 (24) |
| Travel distance toCAR-Ttreatment center, median (mean; IQR) | 50 km (78; 20-101) |
| Temporary stay needed to be close enough to hospital during first month after CAR-T infusion, n (%) | 82 (21) |
| Of whom received financial support from an official authority‡ to rent a temporary stay, n (%) | |
| Yes | 28 (34) |
| No | 39 (48) |
| Not applicable, for example stay with relatives or friends who live close to the hospital | 15 (18) |
| Experienced cytokine release syndrome, n (%) | 243 (62) |
| Unknown | 12 (3) |
| Experienced neurological side effects,n (%) | 163 (42) |
| Unknown | 13 (3) |
| Experienced infections, n (%) | 100 (26) |
| Unknown | 26 (7) |
| Experienced cytopenia(s), n (%) | 290 (75) |
| Unknown | 51 (13) |
| Disease progression after CAR-T therapy, n (%) | 76 (20) |
| Unknown/awaiting response | 29 (7) |
ICU, intensive care unit; IQR, interquartile range; km, kilometer; N, number.
Not applicable for the patients who received allogeneic CAR T-cells (n = 4).
One patient reported 0 days of admission and may have received CAR-T therapy on an outpatient basis.
For example, a health insurance company, the hospital, or the sponsor of the clinical trial.